In vivo genetic screen identifies a SLC5A3-dependent myo-inositol auxotrophy in acute myeloid leukemia

An enhanced requirement for extracellular nutrients is a hallmark property of cancer cells. Here, we optimized an in vivo genetic screening strategy for evaluating dependencies in acute myeloid leukemia (AML), which led to the identification of the myo-inositol transporter SLC5A3 as a unique vulnerability in this disease. In accord with this transport function, we demonstrate that the SLC5A3 dependency reflects a myo-inositol auxotrophy in AML. Importantly, the commonality among SLC5A3-dependent AML lines is the transcriptional silencing of ISYNA1, which encodes the rate limiting enzyme for myoinositol biosynthesis, inositol-3-phosphate synthase 1. We used gain- and loss-of-function experiments to demonstrate a synthetic lethal genetic interaction between ISYNA1 and SLC5A3 in AML, which function redundantly to sustain intracellular myo-inositol. Transcriptional silencing and DNA hypermethylation of ISYNA1 occur in a recurrent manner in human AML patient samples, in association with the presence of IDH1/IDH2 and CEBPA mutations. Collectively, our findings reveal myo-inositol auxotrophy as a novel form of metabolic dysregulation in AML, which is caused by the aberrant silencing of a biosynthetic enzyme. Statement of significance Here, we show how epigenetic silencing can provoke a nutrient dependency in AML by exploiting a synthetic lethality relationship between biosynthesis and transport of myo-inositol. Blocking the function of this solute carrier may have therapeutic potential in an epigenetically-defined subset of AML.

[1]  D. Sabatini,et al.  CRISPR screens in physiologic medium reveal conditionally essential genes in human cells , 2020, bioRxiv.

[2]  W. McCombie,et al.  Abstract 1360: Understanding genetic variation in cancer using targeted nanopore long read sequencing , 2020 .

[3]  M. Dong,et al.  Musashi2 promotes the progression of pancreatic cancer through a novel ISYNA1‐p21/ZEB‐1 pathway , 2020, Journal of cellular and molecular medicine.

[4]  F. Cheng,et al.  Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. , 2019, The Journal of clinical investigation.

[5]  Kıvanç Birsoy,et al.  Targeting extracellular nutrient dependencies of cancer cells , 2019, Molecular metabolism.

[6]  K. Stegmaier,et al.  Salt-Inducible Kinase inhibition suppresses acute myeloid leukemia progression in vivo. , 2019, Blood.

[7]  Aviad Tsherniak,et al.  Extracting Biological Insights from the Project Achilles Genome-Scale CRISPR Screens in Cancer Cell Lines , 2019, bioRxiv.

[8]  M. Ferracin,et al.  Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer , 2019, Cell reports.

[9]  B. Garcia,et al.  The E3 ligase adaptor molecule SPOP regulates fetal hemoglobin levels in adult erythroid cells. , 2019, Blood advances.

[10]  F. Sedlazeck,et al.  Targeted Nanopore Sequencing with Cas9 for studies of methylation, structural variants, and mutations , 2019, bioRxiv.

[11]  D. Sabatini,et al.  Squalene accumulation in cholesterol auxotrophic lymphomas prevents oxidative cell death , 2019, Nature.

[12]  H. Dombret,et al.  Epigenetic Silencing Affects l-Asparaginase Sensitivity and Predicts Outcome in T-ALL , 2019, Clinical Cancer Research.

[13]  Ligong Chen,et al.  The SLC transporter in nutrient and metabolic sensing, regulation, and drug development , 2018, Journal of molecular cell biology.

[14]  J. Kinney,et al.  A Transcription Factor Addiction in Leukemia Imposed by the MLL Promoter Sequence. , 2018, Cancer cell.

[15]  Junwei Shi,et al.  Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma , 2018, eLife.

[16]  J. Hou,et al.  One-pot two-strain system based on glucaric acid biosensor for rapid screening of myo-inositol oxygenase mutations and glucaric acid production in recombinant cells. , 2018, Metabolic engineering.

[17]  R. Hardison,et al.  Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells , 2018, Science.

[18]  Peter W. Laird,et al.  Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer , 2018, Cell.

[19]  Heng Li,et al.  Minimap2: pairwise alignment for nucleotide sequences , 2017, Bioinform..

[20]  Francine E. Garrett-Bakelman,et al.  Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. , 2017, Cancer discovery.

[21]  Ann E. Sizemore,et al.  Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells , 2017, Nature Genetics.

[22]  Winston Timp,et al.  Detecting DNA cytosine methylation using nanopore sequencing , 2017, Nature Methods.

[23]  Michael D. Nyquist,et al.  Harnessing Solute Carrier Transporters for Precision Oncology , 2017, Molecules.

[24]  X. Bai,et al.  Structural biology of solute carrier (SLC) membrane transport proteins , 2017, Molecular membrane biology.

[25]  G. Georgiou,et al.  Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth , 2016, Nature Medicine.

[26]  Thomas M. Norman,et al.  A Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic Dissection of the Unfolded Protein Response , 2016, Cell.

[27]  C. Tanikawa,et al.  Regulation of myo-inositol biosynthesis by p53-ISYNA1 pathway. , 2016, International journal of oncology.

[28]  Navdeep S. Chandel,et al.  Fundamentals of cancer metabolism , 2016, Science Advances.

[29]  S. Ahuja,et al.  L-asparaginase in the treatment of patients with acute lymphoblastic leukemia , 2016, Journal of pharmacology & pharmacotherapeutics.

[30]  Cunqi Ye,et al.  Inositol Hexakisphosphate Kinase 1 (IP6K1) Regulates Inositol Synthesis in Mammalian Cells*♦ , 2016, The Journal of Biological Chemistry.

[31]  A. Saiardi,et al.  Phosphate, inositol and polyphosphates. , 2016, Biochemical Society transactions.

[32]  D. Durocher,et al.  High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities , 2015, Cell.

[33]  K. Giacomini,et al.  SLC transporters as therapeutic targets: emerging opportunities , 2015, Nature Reviews Drug Discovery.

[34]  J. Kinney,et al.  Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains , 2015, Nature Biotechnology.

[35]  S. Schneider,et al.  Inositol transport proteins , 2015, FEBS letters.

[36]  Brian A. Joughin,et al.  A genome-scale in vivo loss-of-function screen identifies Phf6 as a lineage-specific regulator of leukemia cell growth , 2015, Genes & development.

[37]  E. Gottlieb,et al.  Analysis of Cell Metabolism Using LC-MS and Isotope Tracers. , 2015, Methods in enzymology.

[38]  Jun S. Liu,et al.  MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens , 2014, Genome Biology.

[39]  Kristala L J Prather,et al.  Improving D-glucaric acid production from myo-inositol in E. coli by increasing MIOX stability and myo-inositol transport. , 2013, Metabolic engineering.

[40]  C. Soulage,et al.  Potential role and therapeutic interests of myo-inositol in metabolic diseases. , 2013, Biochimie.

[41]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[42]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[43]  Pascale Anderle,et al.  Solute carriers (SLCs) in cancer. , 2013, Molecular aspects of medicine.

[44]  Y. Saunthararajah,et al.  AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. , 2013, Blood.

[45]  L. Martiny,et al.  CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest , 2012, British journal of pharmacology.

[46]  J. Gribben,et al.  Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis , 2012, Cell Death and Disease.

[47]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[48]  S. Rafii,et al.  Directional DNA methylation changes and complex intermediate states accompany lineage specificity in the adult hematopoietic compartment. , 2011, Molecular cell.

[49]  T. Nakanishi,et al.  Solute carrier transporters as targets for drug delivery and pharmacological intervention for chemotherapy. , 2011, Journal of pharmaceutical sciences.

[50]  이연수 Functional genomics reveal that the serine synthesis pathway is essential in breast cancer , 2011 .

[51]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[52]  J. McCubrey,et al.  The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients , 2010, Oncotarget.

[53]  Omar Abdel-Wahab,et al.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.

[54]  L. Nicholson,et al.  Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum‐induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer , 2009, International journal of cancer.

[55]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[56]  V. Ganapathy,et al.  Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. , 2009, Pharmacology & therapeutics.

[57]  Anthony Mancuso,et al.  Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction , 2008, Proceedings of the National Academy of Sciences.

[58]  M. Wunderlich,et al.  Transforming human blood stem and progenitor cells: A new way forward in leukemia modeling , 2008, Cell cycle.

[59]  D. Fennell,et al.  In vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion , 2006, Clinical Cancer Research.

[60]  T. Kipps,et al.  CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. , 2006, Blood.

[61]  S. Chung,et al.  Sodium/myo‐inositol cotransporter‐1 is essential for the development and function of the peripheral nerves , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[62]  S. Roy,et al.  Methylation of the asparagine synthetase promoter in human leukemic cell lines is associated with a specific methyl binding protein , 2004, Oncogene.

[63]  D. Loo,et al.  Kinetics and specificity of the renal Na+/myo-inositol cotransporter expressed in Xenopus Oocytes , 2004, The Journal of Membrane Biology.

[64]  J. Greer,et al.  Loss of Murine Na+/myo-Inositol Cotransporter Leads to Brain myo-Inositol Depletion and Central Apnea* , 2003, The Journal of Biological Chemistry.

[65]  E. O’Shea,et al.  Regulation of Chromatin Remodeling by Inositol Polyphosphates , 2002, Science.

[66]  D. Gagnon,et al.  Identification of a Novel Na+/myo-Inositol Cotransporter* , 2002, The Journal of Biological Chemistry.

[67]  J. Geiger,et al.  The Crystal Structure and Mechanism of 1-l-myo-Inositol- 1-phosphate Synthase* , 2002, The Journal of Biological Chemistry.

[68]  A. Massacrier,et al.  New human sodium/glucose cotransporter gene (KST1): identification, characterization, and mutation analysis in ICCA (infantile convulsions and choreoathetosis) and BFIC (benign familial infantile convulsions) families. , 2002, Gene.

[69]  K. Shimamoto,et al.  An enzymatic cycling method for the measurement of myo-inositol in biological samples. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[70]  J. Issa,et al.  Hypermethylation of CpG islands in the mouse asparagine synthetase gene: relationship to asparaginase sensitivity in lymphoma cells. Partial methylation in normal cells , 2001, British Journal of Cancer.

[71]  E. Ingulli,et al.  Cd47 (Integrin-Associated Protein) Engagement of Dendritic Cell and Macrophage Counterreceptors Is Required to Prevent the Clearance of Donor Lymphohematopoietic Cells , 2001, The Journal of experimental medicine.

[72]  J. Chatton,et al.  Identification of a mammalian H+‐myo‐inositol symporter expressed predominantly in the brain , 2001, The EMBO journal.

[73]  M. Schell,et al.  Back in the water: the return of the inositol phosphates , 2001, Nature Reviews Molecular Cell Biology.

[74]  C. Lagenaur,et al.  Role of CD47 as a marker of self on red blood cells. , 2000, Science.

[75]  E. Imai,et al.  Effects of inhibition of myo-inositol transport on MDCK cells under hypertonic environment. , 1997, The American journal of physiology.

[76]  N. Spinner,et al.  The human osmoregulatory Na+/myo-inositol cotransporter gene (SLC5A3): molecular cloning and localization to chromosome 21. , 1995, Genomics.

[77]  N. Tsukagoshi,et al.  cDNA sequence for rkST1, a novel member of the sodium ion-dependent glucose cotransporter family. , 1994, Biochimica et biophysica acta.

[78]  A. Yamauchi,et al.  Cloning of the cDNa for a Na+/myo-inositol cotransporter, a hypertonicity stress protein. , 1992, The Journal of biological chemistry.

[79]  V. Bansal,et al.  Phosphatidylinositol-derived precursors and signals. , 1990, Annual review of cell biology.

[80]  Michael J. Berridge,et al.  Inositol phosphates and cell signalling , 1989, Nature.

[81]  R. Balaban,et al.  Survey of osmolytes in renal cell lines. , 1988, The American journal of physiology.

[82]  B. Holub Metabolism and function of myo-inositol and inositol phospholipids. , 1986, Annual review of nutrition.

[83]  R. Ramaley,et al.  Purification and properties of Bacillus subtilis inositol dehydrogenase. , 1979, The Journal of biological chemistry.

[84]  B. Kim,et al.  L-asparaginase in the treatment of neoplastic diseases in children. , 1971, Cancer research.

[85]  V. N. Finelli,et al.  THE BIOSYNTHESIS OF FREE AND PHOSPHATIDE MYO-INOSITOL FROM GLUCOSE BY MAMMALIAN TISSUE SLICES. , 1963, The Journal of biological chemistry.

[86]  F. Eisenberg,et al.  Biosynthesis of inositol in rat testis homogenate , 1963 .